Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perlegen sciences, inc.

Eric Peacock1, Phyllis Whiteley

  • 1Perlegen Sciences, Alliance Management, 2021 Stierlin CourtMountain View, CA 94043, USA. eric_peacock@perlegen.com

Pharmacogenomics
|July 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Genomic studies enable personalized medicine by identifying genetic variations linked to drug response and disease. This approach accelerates the development of targeted therapeutics and diagnostics for improved healthcare outcomes.

Area of Science:

  • Genomics
  • Pharmacogenomics
  • Biotechnology

Background:

  • Personalized medicine aims to tailor treatments using genetic information.
  • Previous whole-genome association studies were hindered by technical and financial limitations.
  • Identifying genetic variations is crucial for optimizing drug efficacy and safety.

Purpose of the Study:

  • To make personalized medicine and high-density whole-genome association studies feasible.
  • To identify genetic differences influencing drug efficacy and side effects.
  • To discover genetic variations associated with common diseases.

Main Methods:

  • Analyzing millions of unique genetic variations in thousands of patients.
  • Cost-effective and rapid genetic analysis.

Related Experiment Videos

  • Collaboration with pharmaceutical companies and public sector researchers.

    • Main Results:

    • Enabling prediction of pharmaceutical drug response.
    • Expanding the therapeutic window of treatments.
    • Facilitating the discovery of genetic variations linked to common diseases.

    Conclusions:

    • High-density whole-genome association studies are now achievable.
    • Genetic insights can rescue and reposition pharmaceutical assets.
    • This approach paves the way for novel therapeutics and diagnostics.